{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Gordon MS"],"funding":["Braeburn Pharmaceuticals, Inc.","NIDA NIH HHS","National Institutes of Health","National Institute on Drug Abuse"],"pagination":["108241"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8898543"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["128"],"pubmed_abstract":["This study is a randomized, open label, controlled trial of extended-release buprenorphine (XR-B; BRIXADI™ formulation) versus extended-release naltrexone (XR-NTX) in Maryland jails. A 7-site, open-label, equivalence design will randomly assign 240 adults with a history of opioid use disorder (OUD), stratified by gender and jail, who are nearing release to one of two treatment arms: 1) XR-B in jail or 2) XR-NTX in jail, both followed by 6 monthly injections postrelease at a community treatment program. The primary aim is to determine the rate of pharmacotherapy adherence (number of monthly injections received) of XR-B compared to XR-NTX. The proposed study is innovative because it will be the first randomized clinical trial in the U.S. assessing the effectiveness of receiving XR-B vs. XR-N"],"journal":["Journal of substance abuse treatment"],"pubmed_title":["A clinical protocol of a comparative effectiveness trial of extended-release naltrexone versus extended-release buprenorphine with individuals leaving jail."],"pmcid":["PMC8898543"],"funding_grant_id":["UG1 DA050077","1UG1DA050077"],"pubmed_authors":["Couvillion K","Danner ML","Blue TR","Maher K","Fishman MJ","Murphy SM","Mitchell SG","Jarvis DK","Gordon MS","Wenzel K","Ryan D","Vocci FJ"],"additional_accession":[]},"is_claimable":false,"name":"A clinical protocol of a comparative effectiveness trial of extended-release naltrexone versus extended-release buprenorphine with individuals leaving jail.","description":"This study is a randomized, open label, controlled trial of extended-release buprenorphine (XR-B; BRIXADI™ formulation) versus extended-release naltrexone (XR-NTX) in Maryland jails. A 7-site, open-label, equivalence design will randomly assign 240 adults with a history of opioid use disorder (OUD), stratified by gender and jail, who are nearing release to one of two treatment arms: 1) XR-B in jail or 2) XR-NTX in jail, both followed by 6 monthly injections postrelease at a community treatment program. The primary aim is to determine the rate of pharmacotherapy adherence (number of monthly injections received) of XR-B compared to XR-NTX. The proposed study is innovative because it will be the first randomized clinical trial in the U.S. assessing the effectiveness of receiving XR-B vs. XR-N","dates":{"release":"2021-01-01T00:00:00Z","publication":"2021 Sep","modification":"2025-04-04T23:02:34.182Z","creation":"2025-04-04T23:02:34.182Z"},"accession":"S-EPMC8898543","cross_references":{"pubmed":["33339633"],"doi":["10.1016/j.jsat.2020.108241"]}}